List of Excipients in Branded Drug EXELON

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	EXELON	rivastigmine	0078-0501	.ALPHA.-TOCOPHEROL
Rebel Distributors Corp	EXELON	rivastigmine	21695-357	ALPHA-TOCOPHEROL
Physicians Total Care Inc	EXELON	rivastigmine tartrate	54868-4512	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	EXELON	rivastigmine tartrate	54868-4512	FERRIC OXIDE RED

Exelon Excipient Strategy and Commercial Opportunities in Rivastigmine Products

Last updated: September 25, 2026

Exelon is the brand name for rivastigmine, an acetylcholinesterase inhibitor approved for mild-to-moderate dementia associated with Alzheimer’s disease and Parkinson’s disease. Its commercial platform includes capsules, oral solution, and a once-daily transdermal patch. The strongest excipient-led opportunities are in transdermal delivery, dose-flexible liquid formulations, low-irritation adhesives, and differentiated generic or authorized-generic products.

Rivastigmine’s active ingredient is off-patent in the United States. Commercial protection has shifted from molecule claims to formulation performance, transdermal system design, manufacturing controls, regulatory pathway management, and brand recognition. The patch remains the most technically defensible presentation because bioequivalence, adhesion, drug release, residual drug, skin tolerability, and manufacturing consistency create higher barriers than conventional oral products.

What products and dosage forms does Exelon include?

Exelon is marketed in three principal dosage forms: capsules, oral solution, and transdermal patches. The products contain rivastigmine, generally administered as rivastigmine tartrate in oral products and rivastigmine in the patch system.

Product	Dosage form	Key strengths or delivery rates	Primary excipient strategy
Exelon capsules	Immediate-release hard gelatin capsules	1.5 mg, 3 mg, 4.5 mg, 6 mg	Conventional solid-dose excipients, capsule shell colorants and opacifiers
Exelon oral solution	Oral liquid	2 mg/mL rivastigmine base equivalent	Buffered aqueous vehicle, preservative, pH control and flavor system
Exelon Patch	Once-daily transdermal system	4.6, 9.5 and 13.3 mg/24 hours	Drug-in-adhesive matrix, release liner, backing layer and skin-contact adhesive

The patch has the highest formulation complexity. The oral capsule has the lowest technical barrier and is exposed to generic competition. The oral solution occupies a smaller but strategically useful segment for patients who cannot swallow capsules or require titration flexibility.

What excipients are used in Exelon capsules?

Exelon capsules use a conventional oral solid-dose platform. The product’s inactive ingredients include gelatin and capsule-shell colorants, together with standard formulation materials used to manufacture and fill the capsule. The exact inactive-ingredient presentation can vary by strength and market.

The excipient functions are conventional:

• Gelatin provides the capsule shell.
• Titanium dioxide provides opacity.
• Iron oxide colorants distinguish strengths.
• Solid-dose processing aids support powder handling, encapsulation and content uniformity.
• The capsule formulation provides no major modified-release barrier.

This creates limited scope for premium excipient differentiation. A generic manufacturer can compete through lower cost, supply reliability, capsule appearance, packaging, and pharmacy substitution rather than through a technically distinct formulation.

Potential commercial opportunities include:

1. Vegetarian or non-gelatin capsule shells.
2. Colorant-reduced or colorant-free presentations.
3. Smaller capsule sizes for patients with swallowing difficulty.
4. High-content-uniformity formulations using direct-compression or dry-granulation platforms.
5. Unit-dose adherence packaging for dementia-care facilities.
6. Contract-manufactured private-label rivastigmine products in markets where substitution is permitted.

These changes generally require regulatory support through inactive-ingredient justification, pharmaceutical equivalence and product-quality data. They do not necessarily create enforceable patent protection.

What excipients are used in Exelon oral solution?

The oral solution uses an aqueous vehicle with pH control and preservation. FDA labeling identifies sodium benzoate as an inactive ingredient and describes a buffered liquid formulation containing citric acid and sodium citrate, with flavoring and sweetening components used to improve acceptability.[1]

The formulation objectives are more demanding than those of a simple aqueous solution:

• Maintain rivastigmine stability during shelf life.
• Control pH without creating excessive taste or gastrointestinal intolerance.
• Prevent microbial growth after opening.
• Support accurate dosing through an oral syringe or calibrated dosing device.
• Reduce dosing errors in elderly patients and caregivers.
• Preserve palatability without compromising preservative performance.

Sodium benzoate is commercially relevant because preservative concentration, pH, container closure, and in-use stability are interdependent. A reformulator cannot treat the preservative as an isolated ingredient. The product’s microbial-control strategy must be demonstrated under the intended storage and use conditions.

Commercial opportunities include:

• Preservative-free unit-dose packaging where stability and microbial control can be demonstrated.
• Sugar-free and alcohol-free formulations.
• Taste-masked products using flavor systems, ion-exchange resins or multiparticulate approaches.
• Lower-volume concentrated solutions.
• Oral syringes with integrated dose markings.
• Ready-to-use unit-dose cups for institutional dementia care.
• Formulations designed for feeding-tube administration.

The strongest opportunity is usually not a new excipient alone. It is a coordinated package combining palatability, dose accuracy, stability, container design and caregiver usability.

What excipients and materials protect the Exelon Patch?

The Exelon Patch is a transdermal drug-in-adhesive system. Its functional materials include a drug-containing adhesive matrix, a backing layer and a removable release liner. FDA labeling identifies acrylic and silicone adhesive components and other polymeric materials used to control adhesion, drug incorporation and patch construction.[2]

Transdermal excipient strategy must address five performance variables:

1. Rivastigmine solubility in the adhesive matrix.
2. Drug diffusion through the adhesive and into skin.
3. Adhesion during sweating, bathing and movement.
4. Skin irritation and sensitization.
5. Residual drug and dose delivery at patch removal.

The adhesive is the principal commercial control point. Acrylic and silicone systems have different solubility, tack, cohesion, permeation and irritation profiles. A change in adhesive can alter drug crystallization, release rate, skin permeation and patch adhesion simultaneously.

Other commercially relevant components include:

• Backing films that protect the drug reservoir or matrix from the environment.
• Release liners that permit clean and consistent removal.
• Permeation-control materials.
• Printing inks and overlamination systems.
• Pouch materials that protect the patch from moisture and oxygen.
• Skin-contact layers that reduce edge lift and irritation.

A technically differentiated generic patch can compete through better adhesion, lower skin residue, less irritation, improved pouch opening, or more consistent drug delivery. Those improvements may support product positioning even when they do not generate broad composition-of-matter patent protection.

How strong is the patent estate for Exelon?

Rivastigmine’s active-ingredient protection has expired in the United States. Exelon’s remaining commercial barriers are primarily formulation, system, process and regulatory barriers rather than basic molecule exclusivity.

Protection category	Commercial status
Rivastigmine active ingredient	Off-patent in the United States
Immediate-release capsules	Generic competition established
Oral solution	Generic competition established or available through regulated alternatives, depending on jurisdiction
Transdermal patch	Higher technical barrier; multiple generic systems have entered or sought entry
Method-of-use claims	Limited practical blocking power where broad therapeutic use is no longer enforceable
Formulation and device claims	Potentially relevant if unexpired and listed or asserted
Manufacturing know-how	Important for adhesive mixing, coating, drying, lamination and pouching

The relevant patent analysis must separate listed patents from expired patents, unlisted patents, process patents, and patents that may be asserted in litigation. The FDA Orange Book identifies patents submitted by the NDA holder for approved drug products, but it does not provide a complete inventory of every potentially relevant patent.[3]

For Exelon, patent value is concentrated in transdermal architecture and manufacturing know-how. A patent directed to a specific adhesive composition, drug-loading range, release profile or patch construction can be more commercially relevant than a broad but expired formulation concept.

When did Exelon lose exclusivity?

Exelon’s conventional oral products lost practical exclusivity before the transdermal patch became the principal formulation battleground. The original Exelon capsule NDA was approved in 1997, the oral solution followed in 2000, and the Exelon Patch was approved in 2007.[4]

FDA milestone	Product
1997	Exelon capsules approved
2000	Exelon oral solution approved
2007	Exelon Patch approved
2010s	Generic rivastigmine oral products expanded
2010s-2020s	Generic and alternative rivastigmine patches entered regulated markets

The precise generic-entry date depends on product, jurisdiction, patent certifications, litigation, settlement terms and regulatory approval timing. A single “Exelon expiry date” is therefore commercially misleading. The oral products and patch had different regulatory and patent profiles.

What is the Orange Book status of Exelon?

The Orange Book is the primary U.S. reference for approved drug products, therapeutic equivalence evaluations and patent or exclusivity information submitted for listed products. Exelon is associated with multiple dosage forms and strengths, so Orange Book analysis must be performed at the product and dosage-form level.

The relevant questions are:

• Which Exelon NDA remains listed?
• Which patents were submitted for each dosage form?
• Are the patents expired, delisted or still relevant?
• Which generic applications include Paragraph IV certifications?
• Is a first applicant eligible for 180-day generic exclusivity?
• Do listed patents cover the product, use or delivery system rather than the active ingredient?

An Orange Book listing does not establish that a patent will survive litigation. Conversely, the absence of an Orange Book patent does not eliminate possible exposure to unlisted process, manufacturing or trade-secret claims.

Which companies are challenging Exelon and rivastigmine products?

Generic competition has come from major and specialty pharmaceutical manufacturers operating through abbreviated new drug applications, licensing arrangements and contract manufacturing networks. The competitive field includes companies selling oral rivastigmine products and companies developing or marketing transdermal systems.

The main competitive advantages are:

• Low-cost oral solid-dose production.
• Existing pharmacy distribution.
• Established transdermal manufacturing capacity.
• Experience with adhesive drug delivery.
• Ability to support FDA bioequivalence and quality requirements.
• Access to European, Canadian and emerging-market registrations.

For the patch, competition is less dependent on the active ingredient and more dependent on the ability to demonstrate comparable delivery. A manufacturer with no prior transdermal platform may face higher development costs, longer scale-up timelines and more manufacturing deviations.

What Paragraph IV risks apply to Exelon?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by a proposed generic product. For Exelon, Paragraph IV exposure is most relevant to transdermal patch patents and any later-listed formulation or method patents.

A generic applicant may choose:

• Paragraph I, stating that no patent information is listed.
• Paragraph II, stating that the patent has expired.
• Paragraph III, stating that the applicant will wait until patent expiry.
• Paragraph IV, challenging validity, enforceability or infringement.
• A section viii statement, carving out a patented method of use where permitted.

Capsule and oral-solution products generally present lower patent litigation risk because their formulation architecture is conventional and active-ingredient protection has expired. Patch products present greater risk because a generic system may implicate adhesive, delivery-rate, construction or manufacturing claims.

What generic launch scenarios exist for rivastigmine?

Oral capsule launch

This is the lowest-risk entry scenario. The product can compete primarily on cost and supply. Price erosion can be substantial once several suppliers obtain approval, although institutional and retail contracts may moderate net pricing.

Oral solution launch

The commercial opportunity is smaller but can support higher value per unit if the product improves taste, dose accuracy, storage, or caregiver handling. A differentiated bottle, syringe or unit-dose package can reduce substitution pressure.

Transdermal patch launch

This is the highest-value and highest-risk scenario. A successful entrant must demonstrate comparable drug delivery and maintain commercial adhesion and tolerability. The product may compete on price, but switching can be limited by physician and caregiver preference for a known patch system.

Specialty-care launch

A supplier can target nursing homes, memory-care centers and home-care providers through unit-dose packaging, adherence support and supply contracts. Packaging and service can become more important than minor excipient changes.

What formulation patents and manufacturing IP matter most?

The most valuable patent targets are claims covering:

• Drug-in-adhesive matrices.
• Acrylic-silicone adhesive combinations.
• Rivastigmine loading and concentration ranges.
• Flux or delivery-rate control.
• Patch area and dose-per-area relationships.
• Release liners and backing structures.
• Moisture-protective pouches.
• Low-irritation adhesive systems.
• Manufacturing methods for coating, drying and lamination.
• Control of drug crystallization during storage.

Manufacturing know-how can be as important as patent rights. Transdermal production requires tight control of coating weight, solvent removal, adhesive rheology, web tension, lamination and die-cutting. Small process changes can affect dose uniformity and adhesion.

How does Exelon compare with other Alzheimer’s drugs?

Exelon differs from oral Alzheimer’s drugs because it has a clinically established transdermal route. Donepezil and galantamine are principally oral products, while memantine is available in oral and extended-release forms. Exelon’s patch can reduce the need for repeated oral dosing and may assist patients with swallowing limitations, but it introduces skin tolerability and application-site management issues.

Product	Main delivery options	Excipient opportunity
Exelon/rivastigmine	Capsules, oral solution, patch	Adhesive systems, skin tolerability, caregiver packaging
Donepezil	Tablets, orally disintegrating tablets, solution in some markets	Taste masking, disintegration, low-dose manufacturing
Galantamine	Tablets, capsules, oral solution	Modified release and liquid palatability
Memantine	Tablets, capsules, oral solution	Extended release, liquid dosing and combination products

The patch gives rivastigmine a differentiated delivery platform. It also creates the greatest technical burden for generic competitors.

What licensing deals and partnership opportunities exist?

Commercial opportunities are most credible in four areas:

1. Transdermal technology licensing for adhesive and permeation systems.
2. Regional licensing of approved or near-approved rivastigmine products.
3. Contract development and manufacturing of patches.
4. Co-packaging and adherence programs for institutional care.

A licensee should assess freedom to operate across composition, process, device, packaging and use claims. It should also examine whether the proposed excipient system is supported by prior human exposure, listed in FDA-approved products, or likely to require additional toxicology and regulatory work.

An excipient supplier can pursue a platform strategy by qualifying adhesive systems across several transdermal drugs. This improves the economics of development because the same coating, lamination and pouching infrastructure can support multiple products.

What revenue exposure does Exelon create?

Exelon’s revenue opportunity is concentrated in volume rather than strong branded pricing. Oral rivastigmine is a generic-market product, while the patch can retain higher value because of manufacturing complexity and patient convenience.

Revenue drivers include:

• Number of approved competitors.
• Reimbursement tier placement.
• Institutional purchasing contracts.
• Patch substitution rates.
• Manufacturing yield.
• Adhesive failure and complaint rates.
• Unit-dose packaging premiums.
• Regional regulatory exclusivity.
• Supply reliability.

A transdermal entrant that achieves high yield and low complaint rates can outperform a lower-cost competitor with inconsistent adhesion or pouch integrity. In this market, quality failures can erase nominal cost advantages.

Key Takeaways

• Exelon contains rivastigmine and is marketed as capsules, oral solution and transdermal patches.
• Oral capsules offer limited excipient-led differentiation and face mature generic competition.
• The oral solution creates opportunities in taste masking, preservative strategy, dose accuracy and caregiver packaging.
• The Exelon Patch is the most technically defensible product because adhesive composition, drug release, skin tolerability and manufacturing controls interact.
• Rivastigmine’s active-ingredient protection has expired in the United States.
• Patent risk is concentrated in transdermal formulation, delivery-system construction and manufacturing claims.
• The strongest commercial opportunities are generic or licensed patches, differentiated oral liquids, institutional packaging and transdermal excipient platforms.
• Manufacturing process capability is a material competitive advantage in rivastigmine patches.

Frequently Asked Questions

Can a new excipient create patent protection for a rivastigmine product?

A new excipient can support patent claims when it produces a novel and non-obvious formulation, delivery profile or stability result. The excipient itself must not be the only source of differentiation if the formulation lacks an inventive technical effect.

Is rivastigmine patch development harder than rivastigmine capsule development?

Yes. The patch requires control of adhesive rheology, drug distribution, release, skin permeation, adhesion, irritation, pouching and manufacturing uniformity. Capsules primarily require conventional pharmaceutical-equivalence and quality controls.

Does an FDA-approved excipient eliminate regulatory risk?

No. Prior approval can reduce toxicology and regulatory burden, but the excipient must still be suitable for the proposed route, concentration, dosage form, exposure and patient population.

Can a preservative-free rivastigmine oral solution be commercialized?

Potentially, if the formulation demonstrates acceptable chemical and microbiological stability throughout its labeled shelf life and in-use period. Packaging and single-dose presentation can be central to the design.

Are rivastigmine patch patents the main barrier to generic entry?

They are one of the main barriers. Manufacturing scale-up, comparative delivery testing, adhesion performance, skin tolerability and regulatory documentation are also material entry constraints.

References

1. U.S. Food and Drug Administration. (2024). Exelon (rivastigmine tartrate) capsules and oral solution prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Exelon Patch (rivastigmine transdermal system) prescribing information. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database, Exelon. https://www.accessdata.fda.gov/scripts/cder/daf/